Navigation Links
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
Date:9/13/2011

NEW YORK, Sept. 13, 2011 /PRNewswire/ -- IMMUNE Pharmaceuticals, an emerging leader in the development of Antibody based Therapeutics for the treatment of inflammatory diseases and cancer, today announced the appointment of Dr. Alan Harris, M.D., Ph.D., to the position of Chief Medical Officer.  In this new position, Dr. Harris will play a pivotal  role in the development of Bertilimumab, IMMUNE's phase II ready fully human monoclonal antibody in development for Crohn's Disease and Ulcerative Colitis,  as well as  NanoMAb development candidates in oncology. NanoMAbs are next generation bio- therapeutics with targeting mAbs conjugated to drug loaded nanoparticules.

"Alan brings impressive credentials and pharmaceutical clinical  development experience to the IMMUNE team," said Dr. Daniel Teper, Founder, Chairman of the Board and Chief Executive Officer of IMMUNE Pharmaceuticals.  "We are delighted to attract someone of Alan's caliber to our growing organization.  He will be a tremendous asset and play a critical role as IMMUNE evolves into a clinical stage company."

Dr. Harris led the clinical development of Novartis' somatostatin analogue, octreotide (Sandostatin®), for the treatment of gastrointestinal tumors and endocrine diseases.  More than 20 years after its introduction, Sandostatin remains a leading therapy, with sales reaching $1.4 billion in 2010.  Dr. Harris has also held leadership positions overseeing the clinical development of small molecules and biologics as Vice President of Research at Schering Plough, Therapeutic Head of Endocrinology at Pfizer, Senior Vice President of R & D and Chief Medical Officer at NPS Pharmaceuticals.

Dr. Harris is currently Adjunct Professor in the Department of Pharmacology at NYU Medical Center in New York, and was previously Associate Professor of Medicine at UCLA Medical School and Director of the Division of Clinical Pharmacology
'/>"/>

SOURCE IMMUNE Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
3. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
4. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
5. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
6. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
7. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
8. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
9. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
10. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013   Shareholder rights attorneys  at ... Pharmaceutical, Inc. (NASDAQGS: AVEO) securities has filed a complaint ... Massachusetts .  The complaint alleges that ... Exchange Act of 1934 (the "Exchange Act") between January ... (Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO ) ...
(Date:5/17/2013)... Ill. , May 17, 2013  Sony Biotechnology ... Sony SP6800 Spectral Analyzer (SP6800).  Sony will be exhibiting ... which will be held at the San ... Diego, California , from May 20 - 22.  ... second analytical system, incorporating commercial audio-visual technologies into new ...
(Date:5/17/2013)... -- Research explores data on treatments ...   to   be presented Shire ... global specialty biopharmaceutical company, announces that it will present ... Psychiatric Association (APA) 166th Annual Meeting in ... presented represent Shire,s ongoing commitment to the clinical research ...
Breaking Medicine Technology:Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10
... WIRE)--May 17, 2007 - BioLineRx Ltd. (TASE:,BLRX), ... abstracts containing data from its successfully completed,phase ... class GABA-enhanced,antipsychotic for the treatment of schizophrenia, ... leading scientific,conferences. The data will be presented ...
... Symposium on,Myelodysplastic Syndromes, TAMPA, Fla., May 17, 2007 ... II trial evaluating Revlimid in patients with,an incurable ... today by Dr. Alan List, from the H. ... 9th International,Symposium on MDS currently taking place in ...
Cached Medicine Technology:BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences 2BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences 3Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 2Study Continues to Show Patients With Myelodysplastic Syndromes,Treated With Revlimid are Living Longer and Remaining Transfusion,Independent 3
(Date:5/19/2013)... Boca Raton, FL (PRWEB) May 19, 2013 ... have launched the website YazSideEffects.com in a concerted effort ... effects of the combination birth control drugs Yaz, Yasmin ... website offers a wealth of information on the notorious ... about lawsuits against Bayer Pharmaceuticals. , Yaz, Yasmin ...
(Date:5/18/2013)... Colorado (PRWEB) May 18, 2013 Daily Gossip ... of a new review on their page. John Colston, Daily ... readers to Shaun Hadsall’s revolutionizing 14-Day Rapid Fat Loss ... to sustain that carbs are healthy at a time when ... away from highly caloric products. , The diet is ...
(Date:5/18/2013)... Also known as bariatric surgery ... loss surgery that guarantees patients long-term weight loss. Dr. ... to give readers a brief tutorial on this revolutionary ... at New York City’s Mount Sinai School of Medicine. ... a fellowship in Minimally Invasive Bariatric Surgery. He has ...
(Date:5/18/2013)... (HealthDay News) -- Children who swallow high-powered magnets often ... objects, according to a new study. The researchers, ... Orleans, found that more than 79 percent of children ... or an endoscopic procedure, in which a tube containing ... 21 percent of these cases can be treated through ...
(Date:5/18/2013)... FL (May 18, 2013) There are significant ... commonly used to diagnose or treat gastrointestinal problems, ... (DDW). , A study by New York ... more objective testing may substantially reduce the cost ... Although GERD is believed to affect nearly 25 ...
Breaking Medicine News(10 mins):Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2Health News:Everything You Need to Know About Lap Band Surgery 2Health News:Everything You Need to Know About Lap Band Surgery 3Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2
... the condition appear to have longer soft palates, research shows ... the breathing disturbance known as obstructive sleep apnea have soft ... people without the condition, researchers report. , The soft palate ... the mouth. , A team at the Seoul National University ...
... Feb. 20 Misonix, Inc. (Nasdaq: MSON ... technology, which in Europe is used for the ablation ... has entered into a new, three year, exclusive distribution ... based in Kfar Saba, Israel, for the distribution of ...
... clot-busting drug delivered directly to the brain , , FRIDAY, ... used for years to open blocked coronary blood vessels, ... vessels clogged from strokes, according to new research. , ... treatment or prevention as well, a panel of researchers ...
... hemodialysis (which removes large toxins) reduces the risk of ... (CKD), according to a study appearing in the March ... Society Nephrology (JASN). The results suggest that this ... and those with diabetes. , In patients with CKD, ...
... The hospital services department at Northwest Kidney Centers ... for health care staffing services from The Joint ... is the nation,s oldest and largest standards-setting and ... stand-alone dialysis centers, NKC has a 55-member hospital ...
... th , 2009 in London SOUTHFIELD, ... middle market investment banking firm, is pleased to announce ... and formed a partnership with Robin Young to present ... spinal implant and instrumentation companies. The Spine Technology ...
Cached Medicine News:Health News:Anatomy May Help Identify Sleep Apnea 2Health News:Misonix Announces New Distribution Agreement for Israel 2Health News:Misonix Announces New Distribution Agreement for Israel 3Health News:New Advances May Treat Stroke Faster, Better 2Health News:New Advances May Treat Stroke Faster, Better 3Health News:New Advances May Treat Stroke Faster, Better 4Health News:High-flux hemodialysis prolongs survival in many patients with CKD 2Health News:Northwest Kidney Centers Hospital Services Department Awarded Joint Commission Certification 2Health News:UPDATE: P&M Corporate Finance Announces Partnership with Robin Young to Present the Fifth Annual Spine Technology Summit 2
This high-capacity stand-on scale provides extra sensitivity and support to patients who are unsteady on their feet. Advanced technology compensates for patient movement....
... The 5702 is a heavy-duty, stainless ... for the special needs of bariatric patients. ... handrail assure ease and security. The scale ... weighing, allowing you to weigh a continuous ...
... Endo-PAT2000 is a simple and easy to ... PAT signal is recorded using Itamar Medical's ... is analyzed automatically using proprietary advanced Digital ... within seconds of completing the test. The ...
... synthesized by the parathyroid glands [1,2] ... extracellular calcium concentrations. PTH prevents hypocalcemia ... calcium excretion by the kidney. Following ... is rapidly degraded into 4 fragments: ...
Medicine Products: